MRI Health Risks Makes FDA Reconsider | MRI
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
MRI MRI Health Risks Makes FDA Reconsider

MRI Health Risks Makes FDA Reconsider

Radiology News

FDA advisory panel is set to convene next week to determine whether new regulations may be required for three imaging drugs that contain the chemical gadolinium, a compound that poses significant MRI health risks. The three drugs, which allow for a more thorough image of a body when injected in patients prior to MRI scans, have been associated with nephrogenic systemic fibrosis. NSF is a debilitating and potentially fatal syndrome in which an excessive amount of collagen forms in joints, skin and organs leading to potential paralysis, lung embolisms and eventually death.

According to Business Week, more than 500 lawsuits to date have been filed against makers of drugs containing gadolinium in the US, prompting many major hospitals to discontinue use of the products.

In 2006 the FDA began grouping all imaging products that use gadolinium in one class, claiming in BusinessWeek.com, "There is no definitive evidence establishing that the risk of acquiring NSF is greater for one agent than for the others in the class."

Source: Lawyers and Settlements.com

Discuss more about MRI in our MRI Group

 

Related Articles

Breaking News